COCH Relative Valuation
COCH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COCH is overvalued; if below, it's undervalued.
Historical Valuation
Envoy Medical Inc (COCH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.85. The fair price of Envoy Medical Inc (COCH) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.83 USD , Envoy Medical Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：0.83
Fair
Undervalued
-0.78
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Envoy Medical Inc. (COCH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.26. The thresholds are as follows: Strongly Undervalued below -5.36, Undervalued between -5.36 and -3.31, Fairly Valued between 0.79 and -3.31, Overvalued between 0.79 and 2.84, and Strongly Overvalued above 2.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.01
EV/EBIT
Envoy Medical Inc. (COCH) has a current EV/EBIT of -1.01. The 5-year average EV/EBIT is -2.01. The thresholds are as follows: Strongly Undervalued below -5.87, Undervalued between -5.87 and -3.94, Fairly Valued between -0.08 and -3.94, Overvalued between -0.08 and 1.85, and Strongly Overvalued above 1.85. The current Forward EV/EBIT of -1.01 falls within the Historic Trend Line -Fairly Valued range.
116.19
PS
Envoy Medical Inc. (COCH) has a current PS of 116.19. The 5-year average PS is 105.71. The thresholds are as follows: Strongly Undervalued below -83.75, Undervalued between -83.75 and 10.98, Fairly Valued between 200.44 and 10.98, Overvalued between 200.44 and 295.17, and Strongly Overvalued above 295.17. The current Forward PS of 116.19 falls within the Historic Trend Line -Fairly Valued range.
-0.88
P/OCF
Envoy Medical Inc. (COCH) has a current P/OCF of -0.88. The 5-year average P/OCF is -1.34. The thresholds are as follows: Strongly Undervalued below -4.15, Undervalued between -4.15 and -2.74, Fairly Valued between 0.07 and -2.74, Overvalued between 0.07 and 1.47, and Strongly Overvalued above 1.47. The current Forward P/OCF of -0.88 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Envoy Medical Inc. (COCH) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Envoy Medical Inc (COCH) has a current Price-to-Book (P/B) ratio of -2.62. Compared to its 3-year average P/B ratio of -6.85 , the current P/B ratio is approximately -61.68% higher. Relative to its 5-year average P/B ratio of -6.22, the current P/B ratio is about -57.81% higher. Envoy Medical Inc (COCH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -52.86%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -52.86% , the current FCF yield is about -100.00% lower.
-2.62
P/B
Median3y
-6.85
Median5y
-6.22
-70.00
FCF Yield
Median3y
-52.86
Median5y
-52.86
Competitors Valuation Multiple
The average P/S ratio for COCH's competitors is 0.01, providing a benchmark for relative valuation. Envoy Medical Inc Corp (COCH) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -25.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of COCH decreased by 41.78% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.64K to -15.43K.
The secondary factor is the Revenue Growth, contributed -25.00%to the performance.
Overall, the performance of COCH in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Envoy Medical Inc (COCH) currently overvalued or undervalued?
What is Envoy Medical Inc (COCH) fair value?
How does COCH's valuation metrics compare to the industry average?
What is the current P/B ratio for Envoy Medical Inc (COCH) as of Dec 13 2025?
What is the current FCF Yield for Envoy Medical Inc (COCH) as of Dec 13 2025?
What is the current Forward P/E ratio for Envoy Medical Inc (COCH) as of Dec 13 2025?